| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
BGM Group Ltd.$0.34
+0.02 (+5.24%)
0Pipeline Score NOT_PHARMA
Market Cap
53.72 M
EPS
-
P/E Ratio
-
Value Trade
25.85 K
-3.63 %
Week
-22.71 %
1 Month
-72.19 %
3 Month
-96.31 %
6 Month
-99.74 %
5 Year
-99.85 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
63.35 K
52 Week Range
0.26 - 17.17
% held by Insiders
80.42 %
% held by Institutions
0.11 %
Enterprise Value
-
Total Shares
180.62 M
Short %
0.63 %
Float Shares
40.28 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
0
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 2%
Micro Cap (rank 888 of 905)
Percentile RankClinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in BGM
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
BGM
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
BGM
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
BGM
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
BGM Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
BGM Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
BGMBGM Group Ltd. No. 152 Hongliang East 1st Street, No. 1703, Tianfu New District Chengdu, PRC 610200 People's Republic of China Notice of Extraordinary General Meeting of Shareholders To Be Held on
BGM Group Ltd. has announced an Extraordinary General Meeting scheduled for July 9, 2026. The meeting will address several important resolutions including a Share Capital Reduction and Reorganization, as well as the adoption of new memorandum and articles of association. The Board of Directors has unanimously recommended a vote in favor of these proposals, indicating their potential benefits for shareholders. The Record Date for shareholders entitled to vote is set for June 12, 2026.
Read more →BGMACTING IN CONCERT AGREEMENT This Acting in Concert Agreement (the Agreement ) is executed on
The Acting in Concert Agreement executed on July 5, 2025, involves four parties: Mr. Zhanchang Xin, Ahanzhai Development Limited, Ms. Furong Cao, and LX Management Company Limited. The agreement outlines the arrangement for the parties to act in concert regarding various corporate governance matters of BGM Group Ltd, including decisions related to directors and management. Additionally, the document specifies the decision-making process, representations, warranties, liability for breaches, and mechanisms for resolving disputes under Hong Kong law.
Read more →BGMBGM GROUP LTD INDEX TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS TABLE OF CONTENTS CONTENTS PAGE(S) Unaudited Condensed Consolidated Balance Sheets as of
BGM Group Ltd has released its unaudited condensed consolidated financial statements for the second quarter of 2025. The document includes various balance sheet entries, such as common stock and retained earnings, alongside related party information. This financial data is crucial for assessing the company's current financial position and operational performance. However, the lack of detailed commentary on the results makes it challenging to draw specific conclusions about the company's performance.
Read more →BGMFrom Virtual Agents to Embodied and Industry-Specific AI: BGM Acquires Xingdao Intelligent and YD Network, Advancing AI on Two Fronts Chengdu, China
BGM Group Ltd has announced the acquisition of Xingdao Intelligent and YD Network for a total valuation of RMB800 million, aiming to enhance its artificial intelligence capabilities. This strategic move allows BGM to integrate hardware and software in various applications, including robotics and fintech solutions. The acquisitions are expected to close by the end of June 2025 and will collectively give the acquired companies around 15.6% ownership in BGM. CEO Chen Xin highlighted the importance of multi-agent collaboration and how these acquisitions represent key advancements in AI technology for the company.
Read more →BGMBGM Group Announces Strategic Acquisition of HM Management to Expand AI Application Ecosystem Chengdu, China
BGM Group Ltd. has announced its strategic acquisition of HM Management Company Limited, valued at approximately RMB300 million (US$41.7 million). Through this all-stock transaction, BGM aims to enhance its capabilities in AI-driven enterprise solutions, particularly in industry-specific applications. The acquisition is expected to close in the second quarter of 2025, and it positions BGM to better integrate existing resources while expanding its technology portfolio. The CEO highlighted the importance of this acquisition for innovation in AI agent applications and for maintaining a competitive edge in the market.
Read more →BGMBGM Group Acquires Wonder Dragon to Accelerate Healthcare Strategy
BGM Group Ltd. has announced its acquisition of Wonder Dragon Global Limited, aimed at bolstering its strategy in the healthcare sector. The total transaction value is RMB550 million, with BGM acquiring 100% of Wonder Dragon through the issuance of Class A shares. This acquisition provides BGM with a substantial inventory of premium Qingzhuan dark tea, which the company plans to use for developing health-oriented tea products. BGM is focused on leveraging AI technology in its operations to enhance product development and market distribution in the healthcare space.
Read more →BGMRONS INTELLIGENT TECHNOLOGY (BEIJING) CO., LTD. AND SHENZHEN XINBAO INVESTMENT MANAGEMENT CO., LTD. INDEX TO COMBINED FINANCIAL STATEMENTS CONTENTS PAGE(S) REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM (PCAOB I
RONS Intelligent Technology (Beijing) Co., Ltd. and Shenzhen Xinbao Investment Management Co., Ltd. have released their audited combined financial statements for the fiscal years ending September 30, 2023, and September 30, 2024. The independent auditor's report indicates that the financial statements conform to U.S. GAAP. Despite an increase in revenues, the companies reported significant operational losses and a decline in total assets over the examined period, suggesting challenges in financial performance and stability.
Read more →BGMBGM Acquires YX to Strengthen AI Strategy for Its Intelligent Platform
BGM Group Ltd. has announced its acquisition of YX Management Company Ltd. for $95 million, purchasing 100% of YX's equity interests. This strategic move is aimed at enhancing BGM's AI-driven intelligent platform, DuXiaoBao, by leveraging YX's team, which boasts significant expertise in digital infrastructure and technology commercialization. The acquisition is expected to be completed by June 2025, with YX's shareholders retaining approximately 32.8% of BGM's outstanding shares. The merger highlights the emphasis on AI integration and innovation within BGM's operations in both smart mobility and biopharmaceutical sectors.
Read more →BGMBGM Group Ltd No. 152 Hongliang East 1st Street, No. 1703, Tianfu New District, Chengdu, 610200 People's Republic of China
BGM Group Ltd has formally appointed a new Chairman to its board of directors, effective March 1, 2025. The agreement details the Chairman's responsibilities, compensation, and terms for re-election at the annual shareholders' meeting. This move signals BGM's commitment to strengthening its governance and leadership. The company believes that this new addition will significantly contribute to its future success.
Read more →BGMIn-Depth Analysis of BGM Group: Innovating Pharmaceuticals and Insurance through AI
BGM Group Ltd., based in Chongqing, China, has acquired Rongshu Technology and Xinbao Investment Company, valued at approximately $140 million. This acquisition will enhance BGM's AI-driven insurance business and foster synergy with its new shareholder, AIFU. CEO Xin Chen aims to integrate AI technology to innovate traditional pharmaceutical operations and expand into the health-focused insurance market. However, despite this growth potential, the company's stock has shown recent volatility and remains undervalued in the market.
Read more →BGMSHARE SUBSCRIPTION AGREEMENT THIS AGREEMENT is made on
BGM Group Ltd has entered into a Share Subscription Agreement with Ahanzhai Development Co., Ltd for the issuance of 10,200,000 class B ordinary shares at a price of $0.05 per share, totaling $510,000. The agreement includes conditions related to the issuance and allotment of shares, aspects of payment, and representations made by both parties. Any bank charges related to the transaction will be borne by the Subscriber. The agreement outlines various legal obligations, confidentiality agreements, and dispute resolution procedures in the event of a disagreement between the parties.
Read more →BGMTRANSACTION AGREEMENT BY AND AMONG BGM GROUP LTD, CISG HOLDING LTD, PATRITION LIMITED, GM MANAGEMENT COMPANY LIMITED, DUXIAOBAO INTELLIGENT TECHNOLOGY (SHENZHEN) CO., LTD ( ( ) ) RONS INTELLIGENT TECHNOLOGY (BEIJING) CO.
BGM Group Ltd has entered a transaction agreement involving a significant share exchange with several companies, including GM Management Company and Duxiaobao Intelligent Technology. The agreement specifies that the seller owns 50,000 shares of Target Co., which will be exchanged for approximately 69.99 million Buyer Shares. This transaction is part of a larger reorganization effort aimed at consolidating respective subsidiaries under Target Co. The agreement outlines various conditions and representations that must be met for the transaction to close.
Read more →BGMQilian International Holding Group Limited No. 152 Hongliang East 1st Street, No. 1703, Tianfu New District, Chengdu, PRC 610200 NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON OCTOBER 18, 2024 TO T
Qilian International Holding Group Limited has announced an Extraordinary General Meeting scheduled for October 18, 2024. The meeting will address significant proposals, including adjustments to voting rights for both Class A and Class B Ordinary Shares and amendments to the company's governance documents. The board recommends shareholders vote in favor of all proposals, which aim to enhance shareholder rights and streamline corporate governance. Shareholders must ensure their proxies are submitted correctly to participate in the vote.
Read more →BGMQILIAN INTERNATIONAL HOLDING GROUP LIMITED INDEX TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS TABLE OF CONTENTS Condensed Consolidated Financial Statements Condensed Consolidated Balance Sheets as of M arch 31, 2024 an
Qilian International Holding Group Limited has released its condensed consolidated financial statements for the quarter ending March 31, 2024. The document outlines key balance sheet figures but lacks detailed commentary on the company's financial performance. The report raises concerns regarding the clarity and completeness of the disclosed information, questioning the reliability of the presented data. As such, readers and stakeholders may find it challenging to derive meaningful insights from the provided statements.
Read more →BGMQilian International Holding Group Limited No. 152 Hongliang East 1st Street, No. 1703, Tianfu New District Chengdu, PRC 610200 People's Republic of China Notice of Extraordinary General Meeting of Shareholders To Be Hel
Qilian International Holding Group Limited has announced an Extraordinary General Meeting scheduled for April 19, 2024, to discuss key resolutions including a Share Capital Reorganization. Shareholders will vote on dividing the authorized share capital into various classes of shares. The Board of Directors supports the proposals and urges shareholders to participate in the voting process. The record date for determining eligible voters is set for March 7, 2024.
Read more →BGMQilian International Holding Group Limited No. 152 Hongliang East 1st Street, No. 1703, Tianfu New District, Chengdu, PRC 610200 NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON DCEMBER 5, 2023 TO TH
Qilian International Holding Group Limited is convening an Extraordinary General Meeting for shareholders on December 5, 2023, at their headquarters in Chengdu, PRC. The meeting aims to consider and vote on several proposals, all of which the board endorses with a recommendation to vote 'FOR'. Only shareholders holding ordinary shares as of October 25, 2023, will be eligible to vote. This meeting underscores the company's ongoing commitment to transparency and shareholder engagement.
Read more →BGMFinancial Highlights for the Six Months Ended
For the six months ended March 31, 2023, BGM reported a 9% decrease in revenue, amounting to $29.2 million. Gross profit also declined substantially by 34%, leading to an 83% drop in income from operations. However, net income increased by 76%, attributed to an increase in investment income. The heparin product line experienced significant price competition due to new centralized procurement policies by the PRC government, affecting sales.
Read more →BGMQilian Received a Letter from Nasdaq Related to Regain Compliance
Qilian International Holding Group Ltd received a letter from NASDAQ confirming that it is now in compliance with listing rules after having filed its annual report on Form 20-F. The company had previously faced non-compliance issues due to a delay in the 2022 report submission. Following the timely filing on April 19, 2023, NASDAQ reassured the company of its compliance status. This is crucial for Qilian as it ensures continued trading on the NASDAQ stock exchange.
Read more →BGMQilian Received Notification of Deficiency from Nasdaq Related to not timely Filing of Annual Report Form 20-F
Qilian International Holding Group Ltd has been notified by Nasdaq of non-compliance due to its failure to timely file its annual report on Form 20-F. This notice does not have immediate effects on its listing or trading status. The company now has 60 days to submit a compliance plan, and if accepted, it may receive an extension of up to 180 days to resolve the issue. The company operates as a manufacturer and seller of various pharmaceutical and chemical products in China.
Read more →BGMQilian International Holding Group Ltd Declares Special Cash Dividends to Shareholders Jiuquan, China
Qilian International Holding Group Ltd has declared a special one-time cash dividend of $0.05 per share for shareholders, payable around March 6, 2023. The company reported maintaining decent operating results and a healthy cash flow despite challenges posed by COVID-19. CEO Mr. Zhanchang Xin expressed optimism about improved financial results following China's easing of COVID-19 restrictions. The dividend announcement highlights Qilian's commitment to returning value to its shareholders.
Read more →BGMQilian International Holding Group Limited Reports Financial Results for the First Six Months of Fiscal Year 2022 Jiuquan, China
Qilian International Holding Group Limited Reports Financial Results for the First Six Months of Fiscal Year 2022 Jiuquan, China, September 30, 2022 (GLOBE NEWSWIRE) -- Qilian International Holding Group Limited (Nasdaq: QLI) (the "Company"), a China-based pharmaceutical and c
Read more →BGMQILIAN INTERNATIONAL HOLDING GROUP LTD. Jiuquan Economic and Technological Development Zone Jiuquan City, Gansu Province, 735000 People's Republic of China
QILIAN INTERNATIONAL HOLDING GROUP LTD. Jiuquan Economic and Technological Development Zone Jiuquan City, Gansu Province, 735000 People's Republic of China You are cordially invited to attend the 2022 Annual General Meeting (the "Meeting") of Stockholders of Qilian Internati
Read more →BGMQilian International Holding Group Limited Reports Fiscal Year 2021 Financial Results Jiuquan, China
Qilian International Holding Group Limited Reports Fiscal Year 2021 Financial Results Jiuquan, China, Feburary 11, 2022 /PRNewswire/ -- Qilian International Holding Group Limited (Nasdaq: QLI) (the "Company", "Qilian International", "we", "our" or "us"), a China-based pharmac
Read more →BGMQilian International Holding Group Limited Reports Financial Results for the First Six Months of Fiscal Year 2021 Jiuquan, China
Qilian International Holding Group Limited Reports Financial Results for the First Six Months of Fiscal Year 2021 Jiuquan, China, September 16, 2021 (GLOBE NEWSWIRE) -- Qilian International Holding Group Limited (Nasdaq: QLI) (the "Company"), a China-based pharmaceutical and
Read more →BGMQilian International Holding Group Limited Reports Fiscal Year 2020 Financial Results Jiuquan, China
Qilian International Holding Group Limited Reports Fiscal Year 2020 Financial Results Jiuquan, China, February 11, 2021 - Qilian International Holding Group Limited (Nasdaq: QLI) (the "Company"), a China-based pharmaceutical and chemical products manufacturer, today announced
Read more →BGMQilian International Holding Group Limited Announces Full Exercise of Underwriters' Over-Allotment Option Jiuquan, China
Qilian International Holding Group Limited Announces Full Exercise of Underwriters' Over-Allotment Option Jiuquan, China, January 19, 2021 - Qilian International Holding Group Limited (the "Company") (Nasdaq: QLI), a China-based pharmaceutical and chemical products manufactur
Read more →BGMQilian International Holding Group Limited Announces Pricing of Initial Public Offering Jiuquan, China
International Holding Group Limited Announces Pricing of Initial Public Offering Jiuquan, China, January 11, 2021 - Qilian International Holding Group Limited (the "Company"), a China-based pharmaceutical and chemical products manufacturer, today announced the pricing of its
Read more →Competitive Position
How BGM ranks across every disease it competes inCompetitive Position is a premium feature
See how BGM ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial